| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Naomi Berrie Diabetes Center, Division of Endocrinology, Departments of
*
Medicine,
Surgery, and
Microbiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032; and
Medical College of Georgia, Augusta, GA 30912
Ligation of the receptor for advanced glycation end products (RAGE) occurs during inflammation. Engagement of RAGE results in enhanced expression of addressins and it is therefore, not surprising that previous studies have shown a role of RAGE/ligand interactions in immune responses including cell/cell contact but the role of RAGE in spontaneous autoimmunity has not been clearly defined. To study the role of RAGE/ligand interactions in autoimmune diabetes, we tested the ability of soluble RAGE, a scavenger of RAGE ligands, in late stages of diabetes development in the NOD mouse-disease transferred with diabetogenic T cells and recurrent disease in NOD/scid recipients of syngeneic islet transplants. RAGE expression was detected on CD4+, CD8+, and B cells from diabetic mice and transferred to NOD/scid recipients. RAGE and its ligand, S100B, were found in the islets of NOD/scid mice that developed diabetes. Treatment of recipient NOD/scid mice with soluble RAGE prevented transfer of diabetes and delayed recurrent disease in syngeneic islet transplants. RAGE blockade was associated with increased expression of IL-10 and TGF-
in the islets from protected mice. RAGE blockade reduced the transfer of disease with enriched T cells, but had no effect when diabetes was transferred with the activated CD4+ T cell clone, BDC2.5. We conclude that RAGE/ligand interactions are involved in the differentiation of T cells to a mature pathogenic phenotype during the late stages of the development of diabetes.
This article has been cited by other articles:
|
|
 |
|
  Z. Zhao, C. Zhao, X. H. Zhang, F. Zheng, W. Cai, H. Vlassara, and Z. A. Ma Advanced Glycation End Products Inhibit Glucose-Stimulated Insulin Secretion through Nitric Oxide-Dependent Inhibition of Cytochrome c Oxidase and Adenosine Triphosphate Synthesis Endocrinology, June 1, 2009; 150(6): 2569 - 2576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. I. Hudson, A. Z. Kalea, M. del Mar Arriero, E. Harja, E. Boulanger, V. D'Agati, and A. M. Schmidt Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42 J. Biol. Chem., December 5, 2008; 283(49): 34457 - 34468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, E. M. Akirav, W. Chen, O. Henegariu, B. Moser, D. Desai, J. M. Shen, J. C. Webster, R. C. Andrews, A. M. Mjalli, et al. RAGE Ligation Affects T Cell Activation and Controls T Cell Differentiation J. Immunol., September 15, 2008; 181(6): 4272 - 4278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hiwatashi, S. Ueno, K. Abeyama, F. Kubo, M. Sakoda, I. Maruyama, M. Hamanoue, S. Natsugoe, and T. Aikou A Novel Function of the Receptor for Advanced Glycation End-Products (RAGE) in Association with Tumorigenesis and Tumor Differentiation of HCC Ann. Surg. Oncol., March 1, 2008; 15(3): 923 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Moser, D. D. Desai, M. P. Downie, Y. Chen, S. F. Yan, K. Herold, A. M. Schmidt, and R. Clynes Receptor for Advanced Glycation End Products Expression on T Cells Contributes to Antigen-Specific Cellular Expansion In Vivo J. Immunol., December 15, 2007; 179(12): 8051 - 8058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Herold, B. Moser, Y. Chen, S. Zeng, S. F. Yan, R. Ramasamy, J. Emond, R. Clynes, and A. M. Schmidt Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress J. Leukoc. Biol., August 1, 2007; 82(2): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koyama, T. Shoji, H. Yokoyama, K. Motoyama, K. Mori, S. Fukumoto, M. Emoto, T. Shoji, H. Tamei, H. Matsuki, et al. Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2587 - 2593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology, July 1, 2005; 15(7): 16R - 28R. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Hudson, E. Harja, B. Moser, and A. M. Schmidt Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease: The Next C-Reactive Protein? Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 879 - 882. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cataldegirmen, S. Zeng, N. Feirt, N. Ippagunta, H. Dun, W. Qu, Y. Lu, L. L. Rong, M. A. Hofmann, T. Kislinger, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-{alpha} and NF-{kappa}B J. Exp. Med., February 7, 2005; 201(3): 473 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M Sullivan, T. S. Futers, J. H Barrett, B. I Hudson, M. S Freeman, and P. J Grant RAGE polymorphisms and the heritability of insulin resistance: the Leeds Family Study Diabetes and Vascular Disease Research, February 1, 2005; 2(1): 42 - 44. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
